Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter

Jacob Andersen; Kristoffer B Ringsted; Benny Bang-Andersen; Kristian Strømgaard; Anders S Kristensen

doi:10.1038/srep15650

Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter

Jacob Andersen, Kristoffer B Ringsted, Benny Bang-Andersen, Kristian Strømgaard, Anders S Kristensen

20 Citations (Scopus)

Abstract

The transporters for norepinephrine and dopamine (NET and DAT, respectively) constitute the molecular targets for recreational drugs and therapeutics used in the treatment of psychiatric disorders. Despite a strikingly similar amino acid sequence and predicted topology between these transporters, some inhibitors display a high degree of selectivity between NET and DAT. Here, a systematic mutational analysis of non-conserved residues within the extracellular entry pathway and the high affinity binding site in NET and DAT was performed to examine their role for selective inhibitor recognition. Changing the six diverging residues in the central binding site of NET to the complementary residues in DAT transferred a DAT-like pharmacology to NET, showing that non-conserved binding site residues in NET are critical determinants for inhibitor selectivity. In contrast, changing the equivalent residues in the central site of DAT to the corresponding residues in NET had modest effects on the same inhibitors, suggesting that non-conserved binding site residues in DAT play a minor role for selective inhibitor recognition. Our data points towards distinct structural determinants governing inhibitor selectivity in NET and DAT, and provide important new insight into the molecular basis for NET/DAT selectivity of therapeutic and recreational drugs.

Original language	English
Article number	15650
Journal	Scientific Reports
Volume	5
Pages (from-to)	1-12
Number of pages	12
ISSN	2045-2322
DOIs	https://doi.org/10.1038/srep15650
Publication status	Published - 27 Oct 2015

Access to Document

10.1038/srep15650Licence: CC BY

Cite this

@article{b893d0482bfd48818c74f1685e0aca98,

title = "Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter",

abstract = "The transporters for norepinephrine and dopamine (NET and DAT, respectively) constitute the molecular targets for recreational drugs and therapeutics used in the treatment of psychiatric disorders. Despite a strikingly similar amino acid sequence and predicted topology between these transporters, some inhibitors display a high degree of selectivity between NET and DAT. Here, a systematic mutational analysis of non-conserved residues within the extracellular entry pathway and the high affinity binding site in NET and DAT was performed to examine their role for selective inhibitor recognition. Changing the six diverging residues in the central binding site of NET to the complementary residues in DAT transferred a DAT-like pharmacology to NET, showing that non-conserved binding site residues in NET are critical determinants for inhibitor selectivity. In contrast, changing the equivalent residues in the central site of DAT to the corresponding residues in NET had modest effects on the same inhibitors, suggesting that non-conserved binding site residues in DAT play a minor role for selective inhibitor recognition. Our data points towards distinct structural determinants governing inhibitor selectivity in NET and DAT, and provide important new insight into the molecular basis for NET/DAT selectivity of therapeutic and recreational drugs.",

author = "Jacob Andersen and Ringsted, {Kristoffer B} and Benny Bang-Andersen and Kristian Str{\o}mgaard and Kristensen, {Anders S}",

year = "2015",

month = oct,

day = "27",

doi = "10.1038/srep15650",

language = "English",

volume = "5",

pages = "1--12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter

AU - Andersen, Jacob

AU - Ringsted, Kristoffer B

AU - Bang-Andersen, Benny

AU - Strømgaard, Kristian

AU - Kristensen, Anders S

PY - 2015/10/27

Y1 - 2015/10/27

N2 - The transporters for norepinephrine and dopamine (NET and DAT, respectively) constitute the molecular targets for recreational drugs and therapeutics used in the treatment of psychiatric disorders. Despite a strikingly similar amino acid sequence and predicted topology between these transporters, some inhibitors display a high degree of selectivity between NET and DAT. Here, a systematic mutational analysis of non-conserved residues within the extracellular entry pathway and the high affinity binding site in NET and DAT was performed to examine their role for selective inhibitor recognition. Changing the six diverging residues in the central binding site of NET to the complementary residues in DAT transferred a DAT-like pharmacology to NET, showing that non-conserved binding site residues in NET are critical determinants for inhibitor selectivity. In contrast, changing the equivalent residues in the central site of DAT to the corresponding residues in NET had modest effects on the same inhibitors, suggesting that non-conserved binding site residues in DAT play a minor role for selective inhibitor recognition. Our data points towards distinct structural determinants governing inhibitor selectivity in NET and DAT, and provide important new insight into the molecular basis for NET/DAT selectivity of therapeutic and recreational drugs.

AB - The transporters for norepinephrine and dopamine (NET and DAT, respectively) constitute the molecular targets for recreational drugs and therapeutics used in the treatment of psychiatric disorders. Despite a strikingly similar amino acid sequence and predicted topology between these transporters, some inhibitors display a high degree of selectivity between NET and DAT. Here, a systematic mutational analysis of non-conserved residues within the extracellular entry pathway and the high affinity binding site in NET and DAT was performed to examine their role for selective inhibitor recognition. Changing the six diverging residues in the central binding site of NET to the complementary residues in DAT transferred a DAT-like pharmacology to NET, showing that non-conserved binding site residues in NET are critical determinants for inhibitor selectivity. In contrast, changing the equivalent residues in the central site of DAT to the corresponding residues in NET had modest effects on the same inhibitors, suggesting that non-conserved binding site residues in DAT play a minor role for selective inhibitor recognition. Our data points towards distinct structural determinants governing inhibitor selectivity in NET and DAT, and provide important new insight into the molecular basis for NET/DAT selectivity of therapeutic and recreational drugs.

U2 - 10.1038/srep15650

DO - 10.1038/srep15650

M3 - Journal article

C2 - 26503701

SN - 2045-2322

VL - 5

SP - 1

EP - 12

JO - Scientific Reports

JF - Scientific Reports

M1 - 15650

ER -

Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter

Abstract

Access to Document

Fingerprint

Cite this